Unknown

Dataset Information

0

Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.


ABSTRACT: Small cell lung cancer (SCLC) is of a highly invasive and metastatic lung cancer subtype and there had not been effective targeted therapies. CD56, a cell surface marker highly expressed on most SCLC, is a promising therapeutic target for treatment of this aggressive cancer. In this study, we generated a novel anti-CD56 antibody named promiximab, characterized by high affinity, internalization and tumor specificity. Then, the promiximab was conjugated with a potent DNA alkylating agent duocarmycin via reduced interchain disulfides to yield the promiximab-Duocarmycin (promiximab-DUBA) conjugates. Mass spectrometry analysis showed promiximab-DUBA had an average DAR (Drug-to-Antibody Ratio) of about 2.04. In vitro, promiximab-DUBA exerted strong inhibitory effects on SCLC cell lines NCI-H526, NCI-H524 and NCI-H69, with IC50 values of 0.07 nmol/L, 0.18 nmol/L and 0.29 nmol/L, respectively. In vivo antitumor activity, promiximab-DUBA at the dose of 5 mg/kg and 10 mg/kg every three days with a total of three times were sufficient to induce sustained regression of NCI-H526 tumors over control treatment with promiximab. Mostly, no recurrence was observed until 65 days post treatment with promiximab-DUBA. In the NCI-H69 subcutaneous xenograft model, significant inhibition of tumor growth was also observed following administration of promiximab-DUBA at the dose of 5 mg/kg or 10 mg/kg. Moreover, body weight and histopathology of major organs (liver, spleen, heart, lung and kidney) showed no significant changes after treatment of promiximab-DUBA. In conclusion, promiximab-DUBA is highly efficacious in small cell lung cancer xenograft models, and provides a new immunotherapy approach for SCLC.

SUBMITTER: Yu L 

PROVIDER: S-EPMC5797043 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.

Yu Lin L   Lu Ying Y   Yao Yuqin Y   Liu Yu Y   Wang Yuxi Y   Lai Qinhuai Q   Zhang Ruirui R   Li Wenting W   Wang Ruixue R   Fu Yuyin Y   Tao Yiran Y   Yi Shuli S   Gou Lantu L   Chen Ligong L   Yang Jinliang J  

Oncotarget 20171226 4


Small cell lung cancer (SCLC) is of a highly invasive and metastatic lung cancer subtype and there had not been effective targeted therapies. CD56, a cell surface marker highly expressed on most SCLC, is a promising therapeutic target for treatment of this aggressive cancer. In this study, we generated a novel anti-CD56 antibody named promiximab, characterized by high affinity, internalization and tumor specificity. Then, the promiximab was conjugated with a potent DNA alkylating agent duocarmyc  ...[more]

Similar Datasets

| S-EPMC3984343 | biostudies-literature
| S-EPMC6343809 | biostudies-literature
| S-EPMC6851832 | biostudies-literature
| S-EPMC6457330 | biostudies-literature
| S-EPMC8322431 | biostudies-literature
| S-EPMC6383682 | biostudies-literature
| S-EPMC5408340 | biostudies-literature
| S-EPMC3687800 | biostudies-literature
| S-EPMC6944112 | biostudies-literature
2023-09-20 | GSE233818 | GEO